PFKFB3 CRISPR/Cas9 KO Plasmid (h): sc-404532
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PFKFB3 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the PFKFB3 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PFKFB3 Antibody (3F3): sc-293477
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PFKFB3 CRISPR/Cas9 KO Plasmid (h) | sc-404532 | 20 µg | $397.00 |
Overview
PFKFB3 encodes 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3, a bifunctional enzyme that controls intracellular fructose-2,6-bisphosphate levels to tune phosphofructokinase-1 activity and glycolytic flux. In human cells, PFKFB3 supports high-rate glycolysis and coordinates metabolic adaptation to growth factor signaling, nutrient availability, and stress responses, linking carbohydrate metabolism to cell-cycle progression and biosynthetic demand. Its activity intersects with hypoxia- and oncogene-associated programs and has been studied in contexts where metabolic reprogramming influences proliferation, migration, and inflammatory signaling. Dysregulated PFKFB3 expression and glycolytic control have been reported across multiple disease-relevant models, including cancer metabolism and vascular or immune cell activation.
PFKFB3 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PFKFB3 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the PFKFB3 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the PFKFB3 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PFKFB3 protein expression.
This CRISPR knockout system enables efficient generation of PFKFB3-deficient cell models for investigation of PFKFB3 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting PFKFB3 exon(s) critical for PFKFB3 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple PFKFB3 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by PFKFB3 CRISPR/Cas9 KO Plasmid (h) and PFKFB3 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the PFKFB3 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by PFKFB3 HDR Plasmid (h) and PFKFB3 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by PFKFB3 homology arms to support homology-directed repair at defined PFKFB3 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.